Status: Not yet recruiting
Saruparib in HRDsig+ Solid Tumors
The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational FoundationOne®CDx clinical trial assay.
Participants needed: 124
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Abramson Cancer Center at Penn MedicineUpdated: Sep 22, 2026Locations: 1
Eligibility criteria
Eastern Cooperative Oncology (ECOG) performance status of 0 to 1 [+13]
Reversion variant in the peripheral blood as assessed by a CLIA certified local... [+26]